Lei Li, Li Che, Kevin M. Tharp, Hyo‐Min Park, Maria G. Pilo, Dan Cao, Antonio Cigliano, Gavinella Latte, Zhong Xu, Silvia Ribback, Frank Dombrowski, Matthias Evert, Gregory J. Gores, Andreas Stahl, Diego F. Calvisi, Xin Chen – 22 February 2016 – Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most prevalent types of primary liver cancer. These malignancies have limited treatment options, resulting in poor patient outcomes. Metabolism reprogramming, including increased de novo lipogenesis, is one of the hallmarks of cancer.

Jessica Mellinger, Robert J. Fontana – 18 February 2016

Tracey G. Simon, Hector Bonilla, Peng Yan, Raymond T. Chung, Adeel A. Butt – 18 February 2016 – Statins are associated with delayed fibrosis progression and a reduced risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV). Limited data exist regarding the most effective type and dose of statin in this population. We sought to determine the impact of statin type and dose upon fibrosis progression and HCC in patients with HCV.

Derek M. Tang, Theo Heller, Christopher Koh – 18 February 2016

William N. Hannah, Stephen A. Harrison – 18 February 2016

Jospehine Simonetti, Lisa Bulkow, Brian J. McMahon, Chriss Homan, Mary Snowball, Susan Negus, James Williams, Stephen E. Livingston – 18 February 2016

Gennaro D'Amico, Giuseppe Malizia, Jaime Bosch – 18 February 2016

Chee‐Kiat Tan – 18 February 2016

Robert J. Fontana, Robert S. Brown, Ana Moreno‐Zamora, Martin Prieto, Shobha Joshi, Maria‐Carlota Londoño, Kerstin Herzer, Kristina R. Chacko, Rudolf E. Stauber, Viola Knop, Syed‐Mohammed Jafri, Lluís Castells, Peter Ferenci, Carlo Torti, Christine M. Durand, Laura Loiacono, Raffaella Lionetti, Ranjeeta Bahirwani, Ola Weiland, Abdullah Mubarak, Ahmed M. ElSharkawy, Bernhard Stadler, Marzia Montalbano, Christoph Berg, Adriano M. Pellicelli, Stephan Stenmark, Francis Vekeman, Raluca Ionescu‐Ittu, Bruno Emond, K.

Erick B. Edwards, Ann M. Harper, Ryutaro Hirose, David C. Mulligan – 17 February 2016 – In June of 2013, the Organ Procurement and Transplantation Network (OPTN) implemented regional sharing for Model for End‐Stage Liver Disease (MELD)/Pediatric End‐Stage Liver Disease (PELD) candidates with scores reaching 35 and above (“Share 35”). The goal of this distribution change was to increase access to lifesaving transplants for the sickest candidates with chronic liver disease and to reduce the waiting‐list mortality for this medically urgent group of patients.